Specialty Xenograft and Gene Editing Technology & CRO Services
Whether your focus is on xenograft/PDX drug efficacy studies,
gene editing, or research model creation, our team can help boost your preclinical research.
Trusted By Leading Biotechnology Companies
Your Full-Service Genetic Modeling CRO
Hera BioLabs is a full-service CRO, offering a broad range of in vivo studies in both mouse and rat models. With our state-of-the-art facility, we can complete your in vivo efficacy tumor xenograft or PDX model study in your preferred mouse model or our proprietary SRG OncoRat®.
The SRG OncoRat® is the first commercially available highly immunocompromised rat model, which has been validated for oncology and used routinely for human xenograft studies.
In Vivo Oncology
Cell Line Engineering
Animal Model Creation
In Vivo Oncology
Our comprehensive xenograft efficacy services use the SRG OncoRat® platform as well as NSG mice and other mouse tumor models. Dozens of cancer cell lines and PDX models have been validated for immediate screening and we also routinely establish new tumor models for our clients.
Cell Line Engineering
Whether your research calls for a targeted knockout, base-pair edit or gene expression, our unique Cas-CLOVER targeted nuclease and piggyBac transposase gene integration technologies have you covered.
Leverage our proprietary suite of gene editing tools and our teams experience in over 75 cell lines to make your cell line engineering projects a success.
Animal Model Creation
Need a custom gene edited or transgenic rat or mouse model? From design to delivery we work with your team to create animal models tailored for your pre-clinical research.
AAALAC Accredited Animal Facility & PHS/OLAW Assurance
Dedicated to ensuring the integrity of our science.
Praise for Hera
We love helping our clients streamline their preclinical research process and achieve
exceptional results.
“The tumor uptake rate was to 80-100%, which is a huge advantage because what we could achieve as a statistical significance with 8-12 mice, can be achieved with 5-6 OncoRats.”
Ramesh Narayanan, Ph.D.
Associate Professor of Medicine & Hematology University of Tennessee Health Science Center
“(The) Cas-CLOVER hybrid gene editing system fuses a functionally inactive Cas9 to the site-specific nuclease, Clo51. Cas-CLOVER is targeted using a set of two distinct gRNAs, operating like CRISPR-Cas9, but (the) system has the exquisite specificity of type IIS nucleases and causes no or very few off-target mutations. We can use this high-fidelity system to safely develop off-the-shelf CAR T-cell products.”
Devon H. Shedlock, Ph.D.
Vice President, Preclinical Development, Poseida Therapeutics
Published In Hundreds of Journals
Our research and platform technologies have been presented in leading scientific publications.
Insightful Insights
Stay informed with our latest R&D, model developments, and industry trends on our blog.
- Emerging Trends: Utilizing Humanized Rat Models for Investigating Strategies Against HIV and Associated Pathologies - HIV-associated morbidity and mortality have both been significantly reduced over the past few decades due to the development of safe and effective combination antiretroviral medications. These drugs have provided a great way for protecti... Read More →
- Cotransfect Multiple piggyBac Transposons to Easily Express Complex Proteins - Multiplexed Gene Delivery with piggyBac One of the most widely used approaches in biotechnology and drug development is the generation of cultured human cells that can stably express one or more recombinant gene sequences for further stu... Read More →
- Optimizing Cell Based Research Models with Cas-CLOVER - The creation of cell-based disease and research models can inform drug development programs through mechanism elucidation, isogenic disease models, loss or gain-of-function studies and more. Because of the imprecision and variable transg... Read More →
Accelerate Your Pre-Clinical Cancer Research and Drug Development
Contact us to learn more about our CRO services for oncology research.